TRAVERE THERAPEUTICS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $41.34 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-08-03
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $41.34M, a 6.54% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $38.43M, a 112935.29% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $42.00K, a 99.89% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $40.00K, a 99.88% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $154.94M, a 15.98% increase from fiscal 2016.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $133.59M, a 33.74% increase from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $99.89M, a 254.19% increase from fiscal 2014.
- TRAVERE THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $28.20M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | $41.34M 10-Q · filed 2018-08-03 | $79.77M 10-Q · filed 2018-08-03 | $79.81M derived: sum of 3 quarters · filed 2018-08-03 | $79.85M derived: sum of 4 quarters · filed 2018-08-03 | ||||
| 2018-03-31 | $38.43M 10-Q · filed 2018-07-06 | $38.47M derived: sum of 2 quarters · filed 2018-07-06 | $38.51M derived: sum of 3 quarters · filed 2018-07-06 | $77.31M derived: sum of 4 quarters · filed 2018-08-03 | ||||
| 2017-12-31 | $42.00K 10-K · filed 2018-07-06 | $82.00K derived: sum of 2 quarters · filed 2018-07-06 | $38.88M derived: sum of 3 quarters · filed 2018-08-03 | $154.94M 10-K · filed 2018-07-06 | ||||
| 2017-09-30 | $40.00K 10-K · filed 2018-07-06 | $40.34M 10-Q · filed 2017-11-07 | $38.84M derived: sum of 2 quarters · filed 2018-08-03 | $112.76M 10-Q · filed 2017-11-07 | $76.20M derived: sum of 4 quarters · filed 2018-08-03 | |||
| 2017-06-30 | $38.80M 10-Q · filed 2018-08-03 | $72.42M 10-Q · filed 2018-08-03 | $76.16M derived: sum of 3 quarters · filed 2018-08-03 | $110.11M derived: sum of 4 quarters · filed 2018-08-03 | ||||
| 2017-03-31 | $34.00K 10-K · filed 2018-07-06 | $33.62M 10-Q · filed 2017-05-05 | $37.36M derived: sum of 2 quarters · filed 2018-07-06 | $71.31M derived: sum of 3 quarters · filed 2018-07-06 | $104.62M derived: sum of 4 quarters · filed 2018-07-06 | |||
| 2016-12-31 | $37.33M 10-K · filed 2018-07-06 | $71.27M derived: sum of 2 quarters · filed 2018-07-06 | $104.58M derived: sum of 3 quarters · filed 2018-07-06 | $133.59M 10-K · filed 2018-07-06 | ||||
| 2016-09-30 | $33.95M 10-K · filed 2018-07-06 | $67.26M derived: sum of 2 quarters · filed 2018-07-06 | $96.27M 10-Q · filed 2017-11-07 | $126.71M derived: sum of 4 quarters · filed 2018-07-06 | ||||
| 2016-06-30 | $33.31M 10-K · filed 2018-07-06 | $62.32M 10-Q · filed 2017-08-09 | $92.77M derived: sum of 3 quarters · filed 2018-07-06 | $120.77M derived: sum of 4 quarters · filed 2018-07-06 | ||||
| 2016-03-31 | $29.01M 10-K · filed 2018-07-06 | $59.45M derived: sum of 2 quarters · filed 2018-07-06 | $87.46M derived: sum of 3 quarters · filed 2018-07-06 | $111.53M derived: sum of 4 quarters · filed 2018-07-06 | ||||
| 2015-12-31 | $30.45M 10-K · filed 2017-03-01 | $58.45M derived: sum of 2 quarters · filed 2017-03-01 | $82.52M derived: sum of 3 quarters · filed 2017-03-01 | $99.89M 10-K · filed 2018-07-06 | ||||
| 2015-09-30 | $28.00M 10-K · filed 2017-03-01 | $52.07M derived: sum of 2 quarters · filed 2017-03-01 | $69.44M 10-Q · filed 2016-11-04 | $83.53M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $24.07M 10-K · filed 2017-03-01 | $41.44M 10-Q · filed 2016-08-05 | $55.52M derived: sum of 3 quarters · filed 2017-03-01 | $63.87M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | $17.37M 10-K · filed 2017-03-01 | $17.37M 10-Q · filed 2015-05-11 | $31.46M derived: sum of 2 quarters · filed 2017-03-01 | $39.80M derived: sum of 3 quarters · filed 2017-03-01 | $45.55M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $14.08M 10-K · filed 2015-03-11 | $22.43M derived: sum of 2 quarters · filed 2016-02-26 | $28.18M derived: sum of 3 quarters · filed 2016-02-26 | $28.20M 10-K · filed 2017-03-01 | $28.20M 10-K · filed 2015-03-11 | |||
| 2014-09-30 | $8.35M 10-K · filed 2016-02-26 | $8.35M 10-Q · filed 2014-11-13 | $14.09M derived: sum of 2 quarters · filed 2016-02-26 | $14.12M 10-Q · filed 2015-11-06 | $14.12M 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $5.74M 10-K · filed 2016-02-26 | $5.74M 10-Q · filed 2014-08-14 | $5.77M 10-Q · filed 2015-08-10 | $5.77M 10-Q · filed 2014-08-14 | ||||
| 2014-03-31 | $28.00K 10-K · filed 2016-02-26 | $27.90K 10-Q · filed 2014-05-15 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |